The Regulatory Maze of Ketamine and Psychedelics with Benjamin Brody, MD

[smfadmin (OP)]

📎 Click on me to view all my attachmentsTheme: Deep IndigoMidnight DarkPink & PurpleSlate GraySolarized LightEmerald GreenCyberpunk NeonNordDraculaSunset OrangeWarm AmberOcean BreezeClassic LightCrimson DuskNo theme (plain)

ListAttBBC  |  v6.10  |  2026-09-10  |  Andrew.human & Claude.ai

#	File	Size	Downloads	Info	DL
00	JCP-Podcast-with-Benjamin-Brody-v3-8-31-26.mp3	56.3 MB	2	ℹ️	⬇️
Attachment ID 6240 Filename (display) JCP-Podcast-with-Benjamin-Brody-v3-8-31-26.mp3 File extension mp3 MIME type audio/mpeg Size 56.3 MB (59061935 bytes) Downloads 2 Dimensions n/a Uploaded by Guest Message ID 49567 Attachment type Normal attachment (0) Storage folder ID 2 Thumbnail attach ID none File hash 632f59569e5dde13be1dc446c9d8455f71d2b1e9 Approved Yes Filename (on disk) not found on disk Storage directory unresolved File exists on disk? No
smfadmin — Yesterday at 07:16:14 PM

The Regulatory Maze of Ketamine and Psychedelics with Benjamin Brody, MD

Ketamine now sits in two very different clinical worlds, one tightly monitored, one far less constrained. In this episode, Benjamin Brody, MD joins Ben Everett, PhD to examine what that split means for psychiatrists trying to deliver these treatments safely.

As newer psychedelic therapies move closer to routine practice, the practical questions get harder, not simpler. What belongs in informed consent, what kind of monitoring is actually necessary, and where does a scalable medical model start to break down?